Is ERS up or down today?
ERS is down 0.48% today, last at 136.04. This stock moved -0.48% versus the prior close.
ERS · ERS
ERS (ERS) is trading at 136.04, down 0.48% on the session. ERS sits at the 50% mark of its 52-week range.
Leading the coverage: “Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st” (Google News Company, 7d ago). ERS is +3.36% since story.
ERS trades on a trailing P/E of 13.5.
Analyst firms are mostly reiterating — no strong directional shift lately.
ERS is down 0.48% today, last at 136.04. This stock moved -0.48% versus the prior close.
Leading the coverage: “Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st” (Google News Company, 7d ago). ERS is +3.36% since story. Dominant story: Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show - The American Journal of Managed Care (1 source, neutral) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show - The American Journal of Managed Care
Roivant and Pulmovant to Present Phase 2 PHocus Study Results of Mosliciguat in PH-ILD at ERS 2026 - Quiver Quantitative
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)? - simplywall.st
ERS coming for high-net-worth individuals - Times of Eswatini